Overview

Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
0
Participant gender:
All
Summary
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborators:
Hoffmann-La Roche
Roche Pharma AG
Treatments:
Interferon-alpha
Peginterferon alfa-2a
Criteria
Inclusion Criteria:

- Completion of HALT-C Trial, in either treatment or non-treatment arm

Exclusion Criteria:

- Non-completion of HALT-C Trial

- Patients who do not wish to be treated with peginterferon after the first portal
pressure measurement

- Hepatocellular Carcinoma

- Underlying autoimmune disorder

- Currently being treated with immune suppressive agent

- Illicit drug use

- Alcohol use of more than 6 grams per day

- Advanced cardiopulmonary disease

- Uncontrolled diabetes mellitus

- Patients who, in the opinion of the investigator, should not participate in this trial